139 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
. Previously he served as Vice President of Corporate Development at Gilead Sciences, Inc., where he was responsible for development and negotiation … director due to her employment as Chief Executive Officer of the Company.
Board Oversight of Risk Management
Our management is primarily responsible
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
". Under the terms of the License Agreement, ReproNovo, a reproductive medicine company, is responsible for all future development and commercialization … will be responsible for post-marketing commitments in their respective territories. Under the terms of the agreement, Ultragenyx made an upfront payment
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
” means, with respect to the efforts to be expended by a Party in carrying out activities for which it is responsible under this Agreement, the level … or councils in the Territory responsible for granting Regulatory Approvals and otherwise regulating the manufacture , distribution, marketing and sale
10-K
2023 FY
EX-31.2
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
flows of the Company as of, and for, the periods presented in this report;
The Company’s other certifying officer(s) and I are responsible
10-K
2023 FY
EX-31.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
and cash flows of the Company as of, and for, the periods presented in this report;
The Company’s other certifying officer(s) and I are responsible
10-K
EX-19.1
0g2vmc 3m
27 Mar 24
Annual report
5:20pm
10-K
EX-4.2
6c5kr 83o10
27 Mar 24
Annual report
5:20pm
8-K
EX-99.1
fqn3tt8lak8kcl
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
S-8
EX-5.1
nsslw
23 Jan 24
Registration of securities for employees
4:16pm
8-K
EX-99.1
y50tqmek5y8j2nz f0w
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-3.1
uj7f0v
18 Dec 23
Current report (foreign)
4:10pm
6-K
EX-99.2
rm5eqd8ef9zu97fjvjo5
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
gvpa7 p36p
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
mis77w skdpr
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.2
te34b
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
9qpil 1s6
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
UPLOAD
lon2 7hulbg
24 Aug 22
Letter from SEC
12:00am
CORRESP
fiet2qhi0vqb468p
19 Aug 22
Correspondence with SEC
12:00am
UPLOAD
e2h9doejg7x
8 Aug 22
Letter from SEC
12:00am
6-K
EX-3.1
u3yzupcipb5n9m46c
17 May 22
Current report (foreign)
8:26am